Synthesis, Characterization, DFT Calculations and Anticoagulant Activity of Symmetrical and Unsymmetrical N-Aryl Thiourea Derivatives

[1]Rekia Nabti, [1]Nasser Belboukhari, [1]Khaled Sekkoum, [2]Noureddine Boulenouar, [3]Houssem Boulebd and [4]Salah Akkal*

[1]*Bioactive Molecules and Chiral Separation Laboratory, Faculty of exact sciences, Tahri Mohammed's University Bechar, Algeria*

[2]*El-Bayadh University Center. Phytochemistry and Organic Synthesis Laboratory.*

[3]*Laboratory of Synthesis of Molecules with Biological Interest, University of Frères Mentouri Constantine 1, Constantine, Algeria.*

[4]*Unité de Recherche Valorisation des Ressources Naturelles, Molécules Bioactives et Analyses Physicochimiques et Biologiques. Université Constantine1, Route d'Aïn El Bey, 25000, Constantine, Algérie.*

salah4dz@yahoo.fr*

(Received on 7th November 2022, accepted in revised form 13th September 2023)

Summary: The present study reports a methodology for the synthesis of symmetrical and unsymmetrical thiourea derivatives 1-9, which have been prepared in good overall yields from condensation reactions between phenylisothiocyanate and different primary amines. The structures of all products were confirmed by the spectroscopic analysis (UV, IR, and NMR). These derivatives were tested for anticoagulant activity using PT and APTT reagents, and those reagents are considered also a controller, the results showed that the theN-aryl thiourea derivatives have very high anticoagulant activity. Theoretical calculations based on DFT/B3LYP method have been performed in order to get insights into the molecular geometry and chemical reactivity of the studied compounds.

Keywords: Thiourea, Phenylisothiocyanate, Anticoagulant Activity, PT reagent, APTT reagent.

Introduction

In 1873 [1], Nencki have synthesized for the first time an emerging class of those compounds Due to its unique reactivity, Thiourea derivatives are used widely for the synthesis of natural products and biologically active compounds. Owing to the sulfur atom contained in these derivatives, they are widely described in literature [2-4], and synthesized commonly with different methods for example: Clara G.M de Oliveira et al, have proposed the synthesis of thiourea derivatives using Benzoyle Chloride added to a solution of ammonium [5], while Zainab Ngaini et al have prepared Hexasubstituted thiourea via a condensation of isothiocyanate cyclophosphazen intermediates with a series of aromatic amine and amino acid in one pot reaction system [6]. MoroverNongnit et al have synthesized thiourea by using ethanamine and isothiocyanatonaphtalene in the Chloroform (CHCl3) solution [7]. Whereas Sanna et al have prepared thiourea derivatives using ethanamine in anhydrous acétonitrile with an appropriate isothiocyanate and the mixture was refluxed for 8 hours [8]. Furthermore I.V.Kulakov et al have synthesized thiourea derivatives using an isothiocyante prepared added to anabasine under mild condition [9]. In another case Cheng Yinan et al have proposed the synthesis of new thiourea derivatives via cyclo-addition reaction of 3-mercaptobutan-2-one and methyl 3-substitutedsilyl propiolate, selective hydrolysis of ester, isothiocyanatation and amination [10]. Likewise, Alexandra Kowalczyk et al have prepared thiourea derivatives using anazidines in reaction with isothiocyanate [11]. In addition, Jian Wu et al have propounded a synthesis of thiourea derivatives from acylisothiocyanate and a suitable fluorinated aromatic amine [12]. While Jonna stefanska et al have prepared the thiourea derivatives from a solution of amine derivatives in acétonitrile in reaction with appropriate isothiocyanate [13]. Otherwise Azim Ziyaei et al have synthesized thiourea derivatives via primary amines and carbon disulfide in 1-butyl-3-methylimidazolium chloride [14]. Whilst Najmedin Azizi et al have synthesized symmetrical thiourea derivatives by reacting primary amines with carbon disulfide in biocompatible basic choline hydroxide [15]. Via rational modification of thiourea derivative structures, it is possible to obtain a wide range of compounds with high pharmacological activity and low side effects. Over the last two centuries, the synthesis and properties of thiourea derivatives have been widely studied, especially for their biological activities [16-19], the thiourea moiety is a significant synthon responsible for a large number of biological activities, citing for example: antistaphylococcal activity, corrosion inhibitor for carbon steel [5]; antimicrobial activity [8,20-24]; anti-tubercular, antithyroid [25]; antiviral activity [8,25-27];

***To whom all correspondence should be addressed.**

antibacterial [11, 20, 28]; antifungal [8, 12, 21, 25, 29, 30]; cytotoxic effects [11,31]; plant growth regulating [32]; herbicidal [32, 33]; antioxidant activities [34]; analgesic [32-34]; antitumor agents [23, 35-37]; antiaggregant [38]; anti arrhythmic drug [39]; local anesthetic [40]; antihyperlipidemic activities [41]; some thiourea derivatives are effective anticancer [42, 43];and found to inhibit HIV reverse transcriptase [8, 37]; lardivicidal activities [44]; antileishmanial activity [45]. The synthesis of new thiourea derivatives was achieved by reacting different amines and phenylisothiocyanate (Usually used as a creative intermediate in the synthesis of thiourea derivatives). The aim of this work is to indicate a new anticoagulant activity of these newderivatives as was the case in our previous works [46-53].

Experimental

Materials and Methods

Reagents and solvents

- Phenylisothiocyanate was purchased from FlukaChemika.
- The primary amines used were: Ethylamine, O-Toluidine, O-Anisidine, 4-Chloroaniline, 2-Chloroaniline, Aniline, Triethylamine, Nitro-2-Aniline, and Tert-butylamine, all of which were purchased from Sigma-Aldrich.

Apparatuses

- UV spectra were obtained in several solvents with UNI- CAM UV300 spectrophotometer assisted to desktop computer.
- IR-Spectra were recorded with an AGILENT Cary 630 FTIR spectrophotometer with a diamond ATR accessory for solid and liquid samples, requiring no sample preparation; wavenumbers are given in cm-1.
- NMR analysis were recorded with superconducting electromagnet made by the brand Bruker actively armored of 400MHz frequency monitored by AVANCE III HD console, corresponding to 9.4 Tesla magnetic field, and an exploitation software TOPSPIN 3.5 PL6.
- Melting points were determined by Büchi® melting point apparatus Model B-545 with capillary tubes, temperature range up to 400 °C.

Synthesis of symmetrical and unsymmetrical N-aryl thiourea derivatives

Phenylisothiocyanate (5mmol) and the appropriate primary amine (5mmol) were mixed in Ethanol solution (5ml), the mixture was putted in ice bath (0°C) for 20 minutes. After that it was evaporated at 25°C for 48 hours, and a crystallized product was obtained.

Spectroscopic data

1-ethyl-3-phenylthiourea, $C_9H_{12}N_2S$ (**1**), this compound was obtained as a crystallized white solid, yield 82% , MP: 90°C, UVmax (MeOH, nm): 295.6 (Band I); 300.1 (Band II), IR (KBr, cm-1): 3300 (NH, medium), 3056.4 (C-H aromatic, medium), 2970 (C-H, strong) 2113.4 (R-N=C=S), 1591.6 (C=C aromatic, variable), 1390 (C-H (CH3), strong), 1200.2 (CN, medium); 1025.0 (C-O, strong), 745.5 (C-H aromatic, strong). 1H NMR (400 MHz, DMSO, ppm): 9.40 (s, 2H, H-7, H-10.); 7.06 – 7, 40 (m, 6H, H-1, H-2, H-3, H-4, H-6, H-10,); 3.48 (m, 2H, H-11); 1.11 (t, 3H, H-12). 13C NMR (101 MHz, DMSO, ppm):180.61 (C=S); 139.77 (C-1); 124.52 (C-2, C-6); 129.06 (C-3, C-5); 123.61 (C-4); 39.16 (C-N); 14, 66 (CH_3).

1-phenyl-3-(o-tolyl)thiourea, $C_{14}H_{14}N_2S$ (**2**), this compound was obtained as a crystallized white solid, yield 90%, MP: 141°C, UVmax (MeOH, nm): 290.3 (Band I); 300.2 (Band II), IR (KBr, cm^{-1}): 3332.2 (NH, medium), 3123.5 (C-H aromatic, medium), 2944.6 (C-H, strong), 2109.7 (R-N=C=S), 1595.3 (C=C aromatic, variable), 1349.3 (C-H (CH3), strong), 1207.7 (CN, medium), 1110.7 (C-O, strong), 760.4 (C-H aromatic, strong). ^{1}H NMR (400 MHz, DMSO, ppm): 9.64 (s, 3H, H-7); 9.29 (s, 1H,H-10); 7.49 (m, 1H, H-4, H-6); 7.10 – 7.34 (m, 1H, H-1, H-2, H-3, H-13, H-14, H-15, H-16); 2.25 (s, 2H, H-17). ^{13}C NMR (100 MHz, DMSO, ppm): 180.92 (C=S); 140, (C-1); 138,27 (C-1'); 135.27 (C-2); 130.80 (C-3); 126.92 (C-6); 128.89 (C-3', C-5'); 128.47 (C-5); 126.56 (C-4); 124.87 (C-6', C-2'); 18.35 (CH_3).

1-(2-methoxyphenyl)-3-phenylthiourea, $C_{14}H_{14}N_2OS$ (**3**), this compound was obtained as a crystallized white solid, yield 92% , MP: 127.1°C, UVmax (MeOH, nm): 288.6 (Band I); 300.6 (Band II), IR (KBr, cm-1) : 3358.3 (NH, medium), 3000.5 (C-H aromatic, medium), 2113.4 (R-N=C=S), 1591 (C=C aromatic, variable), 1370 (Ctet-H (CH3), strong), 1241.2 (C-O, strong), 1200.2 (C-O, strong), 745 (C-H aromatic Mono-substituted, strong), 689.6 (C-H aromatic Mono-substituted, strong). ^{1}H NMR (400 MHz, DMSO, ppm): 9.14 (s, 1H, H-7, H-10); 7.94 (d, 1H, H-16); 7.53 (d, 1H, H-4, H-6); 7.34 (m, 1H, H-1, H-3); 7,14 (m, 1H, H-2); 7.05 (dd, 1H, H-14); 6.92 (td, 1H, H-15); 3.31 (dd, 1H, H-13); 2.08 (s, 3H, H-18).^{13}C NMR (101 MHz, DMSO, ppm): 179.82 (C=S); 152.21 (C-2); 139.79 (C-1'); 128.91 (C-1); 128.16 (C-3', C-5');

126.21 (C-6', C-2'); 126.09 (C-6); 125 (C-4'); 124.18 (C-4); 120.26 (C-5); 111.92 (C-3); 56.19 (O-CH_3).

1-(4-chlorophenyl)-3-phenylthiourea, $C_{13}H_{11}ClN_2S$ (4), this compound was obtained as a crystallized white solid, yield 64% , MP: 150°C, UVmax (MeOH, nm): 288.4 (Band I); 300.9 (Band II), IR (KBr, cm^{-1}): 3343.3 (NH, medium), 3026.6 (C-H aromatic, medium), 2109 (R-N=C=S), 1599 (C=C aromatic, variable), 1084.7 (CN, medium), 708.2 (C-Cl, medium). ^{1}H NMR (400 MHz, DMSO, ppm): 10.5 (s, 1H, H-7, H-10); 9.84 (d, 1H, H-12, H-16); 7.52 (d, 1H, H-4, H-6); 7.46 (d, 1H, H-13, H-15); 7.34 (m, 1H, H-1, H-3); 7.13 (dd, 1H, H-2). ^{13}C NMR (100 MHz, DMSO, ppm):180.19 (C=S); 139.76 (C-1'); 138.98 (C-1); 128.96 (C-3', C-5'); 128.74 (C-3, C-5); 128.71 (C-4); 125.73 (C-2, C-6); 125.05 (C-6', C-2'); 124.18 (C-4').

1-(2-chlorophenyl)-3-phenylthiourea, C13H11ClN2S (5) , this compound was obtained as a crystallized white solid, yield 92% , MP: 157.8°C, UVmax (MeOH, nm): 289,7 (Band I); 300,6 (Band II), IR (KBr, cm^{-1}): 3302.4 (NH, medium), 3034.1 (C-H aromatic, medium), 2109.7 (R-N=C=S), 1591 (C=C aromatic, variable), 1028.7 (CN, medium), 745.5 (C-Cl, medium). ^{1}H NMR (400 MHz, DMSO, ppm): 9.76 (s, 1H, H-7, H-10); 7.50 (d, 1H, H-16); 7.48 (d, 1H, H-4, H-6); 7,30 -7.35 (m, 1H, H-1, H-3, H-13, H-15); 7.10-7.14 (m, 1H, H-2, H-14). ^{13}C NMR (100 MHz, DMSO, ppm): 180.14 (C=S); 139.94 (C-1'); 130,38 (C-1); 129.27 (C-3); 129.19 (C-5); 128.91 (C-3', C-5'); 126.40 (C-2); 124.90 (C-6); 124.13 (C-2', C-6'); 123.79 (C-4); 114,37 (C-4').

1,3-diphenylthiourea, *C13H12N2S* (6), this compound was obtained as a crystallized white solid, yield 90% , MP: 152°C, UVmax (MeOH, nm): 284,6 (Band I); 300,3 (Band II), IR (KBr, cm-1): 3300 (NH, medium), 3034.1 (C-H aromatic, medium), 2113.4 (R-N=C=S), 1595 (C=C aromatic, variable), 1069.7 (CN, medium), 685.8 (Ctri-H of -HC=CH-, strong). ^{1}H NMR (400 MHz, DMSO, ppm): 8.2 (s, 1H, H-7, H-10); 7.57 (m, 1H, H-4, H-6, H-12, H-16); 7.36 (m, 1H, H-1, H-3, H-13, H-15); 7, 16 (m, 1H, H-2, H-14). 13C NMR (101 MHz, DMSO, ppm): 179.51 (C=S); 139, 39 (C-1, C-1'); 128 (C-3, C-5, C-5', C-3'); 125,38 (C-2, C-6); 123,91 (C-4, C-4').

1-(2-nitrophenyl)-3-phenylthiourea, $C_{13}H_{11}N_3O_2S$ (7) , this compound was obtained as a crystallized white solid, yield 86% , MP: 52°C, UVmax (MeOH, nm): 288.4 (Band I); 300.6 (Band II), IR (KBr, cm^{-1}): 3343.4 (NH, medium), 3049 (C-H aromatic, medium), 2113.4 (R-N=C=S), 1543 (C=C aromatic, variable), 1520.8 (N=O, strong), 1543.1 (N-O, strong), 1200 (C-N, medium), 738 (Ctri-H aromatic Mono-substituted, strong), 685.8 (C-H aromatic Mono-substituted, strong). ^{1}H NMR (400 MHz, DMSO, ppm): 9.4 (s, 1H, H-7, H-10); 8.29 (dd, 1H, H-13); 8.05 (dd, 1H, H-16); 7.65 (td, 1H, H-15); 7.57 (m, 1H, H-4, H-6); 7.40 (m, 1H, H-14); 7.36 (m, 1H, H-1, H-3); 7,16 (m, 1H, H-2). ^{13}C NMR (100 MHz, DMSO, ppm): 176.69 (C=S); 137.04 (C-2); 136.92 (C-1'); 136.70 (C-1); 134.48 (C-5); 128.48 (C-3', C-5'); 126.63 (C-3), 125.38 (C-6', C-2'); 125.34 (C-6); 123.91 (C-4'), 118.93 (C-4).

1-(tert-butyl)-3-phenylthiourea, $C_{11}H_{16}N_2S$ (**8**), this compound was obtained as a crystallized yellow solid, yield 91% , MP:121°C,UVmax (MeOH, nm): 286 (Band I); 300.6 (Band II), IR (KBr, cm^{-1}): 3380.7 (NH, medium), 3019 (C-H aromatic, medium), 2959.5 (C-H, strong), 2109.7 (R-N=C=S), 1520 (C=C aromatic, variable), 1203 (C-O, strong), 1155.5 (C-N, medium), 711 (C-H of -HC=CH-, strong). ^{1}H NMR (400 MHz, DMSO, ppm): 10,40 (s, 1H, H-7, H-10); 9,91 (s, 1H, H-10); 7,97 (dd, 1H, H-4, H-6); 7,03 (dd, 1H, H-1, H-3); 6,62 (m, 1H, H-2); 2,09 (s, 3H, H-12, H-13, H-14). 13C NMR (101 MHz, DMSO, ppm): 180,71 (C=S); 146,66 (C-1); 136,13 (C-3, C-5); 125,66 (C-6, C-2); 123,99 (C-4); 115,86 (C-N); 14,38 (CH_3).

1-(2-ethoxyphenyl)-3-phenylthiourea, $C_{15}H_{16}N_2OS$ (**9**), this compound was obtained as a crystallized orange solid, yield 93% , MP: 139,8°C, UVmax (MeOH, nm): 287.2 (Band I); 300.3 (Band II), IR (KBr, cm^{-1}) : 3309.9 (NH, medium), 3168.2 (C-H aromatic, medium), 2981.9 (Ctet-H, strong), 2113.4 (R-N=C=S), 1591 (C=C aromatic), 1233.7 (C-O, strong), 1155 (C-N, medium), 1114.5 (C-O, strong), 738 (C-H of -HC=CH-). ^{1}H NMR (400 MHz, DMSO, ppm): 9.0 (s, 1H, H-7, H-10); 8.03 (dd, 1H, H-16); 7.53 (d, 1H, H-4, H-6); 7.36 (m, 1H, H-1, H-3); 7.16 (tt, 1H, H-2); 7.01- 7.12 (m, 1H, H-14, H-15); 6.92 (m, 1H, H-13); 4.07 (q, 2H, H-18); 1.32 (t, 3H, H-19). ^{13}C NMR (100 MHz, DMSO, ppm): 179.48 (C=S); 151.17 (C-2); 139.50 (C-1'); 129.12 (C-1); 128.36 (C-3', C-5'); 126.03 (C-6', C-2'); 125.57 (C-4'); 125.28 (C-4), 124.43 (C-6), 120.21 (C-5), 112.83 (C-3), 64.42 (O-CH_2), 15.16 (CH_3).

Anticoagulant activity

To achieve the goal of this work which is the anticoagulant activity; we chose 100 healthy people (without chronic diseases, Non-smokers...), by specifying the age group (20-40 years) with equal distribution (Male/Female) to avoid the external factors as much as possible. Also that, Activated partial thromboplastin time (APTT), and Prothrombin time (PT) coagulation tests were performed using normal human plasma. Coagulation was expressed as clotting time (unit in second). We prepared the synthesized

products in four increasing concentrations (C1=20µg/mL, C2=40 µg/mL, C3=80 µg/mL, C4=100µg/mL), firstly, in a dry tube, 90 µl of citrated serum was added to 10 µl of the sample and incubated in a water bath for 3 minutes, then 200 µl of PT reagent (which were placed in a dry tube and incubated at 37°C water bath to activate it) was added and mixed with the reactor, when the fibrin (coagulation) is obtained the timer is stopped and the time recorded corresponds to the appropriate percentage of coagulation. While for the APTT assay, the citrated human plasma (90 µl) was mixed with the sample (10 µl), and the APT reagent (100 µl), the reactor was incubated for three minutes at 37°C. The coagulation time was recorded when the fibrin appears, by a timer.

Computational details

Gaussian09 software [55] has been used for all density functional theory (DFT) calculations of this study. The B3LYP functional [56, 57] and the 6-311G (d,p) basis set have been used for all calculations. This approach has been used successfully by several research groups and good agreement between theory and experiment was found [58, 59]. All the ground states were confirmed by vibrational frequency analysis (no imaginary frequency).

Results and Discussion

Synthesis of N-aryl thiourea derivatives

The synthesis of N-aryl thiourea derivatives (compounds 1- 9) was achieved directly from phenylisothiocyanate, which was treated with various primary amines dissolved in Ethanol, in an ice bath (0°C), without addition of any catalyst as shown in Fig 2. The reaction yields ranged 60% to 93% as shown in Table 1. The structures of the synthesized compounds were confirmed by the analysis of their spectral data, including UV, IR, 1H NMR and 13C NMR; our synthesis procedure showed a better range of yields than that presented by Muhammad Taha et al [54], who performed the same synthetic route using dichloromethane as the solution and leave the reaction for 1-1.5 hours. Although our procedure may be simpler and faster than the one used by Muhammad Taha et al [54], we have seen good results in terms of yield of thiourea derivatives.



Fig 1: Structure of Thiourea derivatives.



Fig. 2: Synthesis of Thiourea derivatives.

Table-1: The characteristics of the synthesized products [64,65].

Product	Yield %	MP
 1	82%	90°C
 2	90%	141°C
 3	92%	127.1°C
 4	64%	150°C
 5	92%	157.8°C
 6	90%	152°C
 7	86%	152
 8	91%	121°C
 9	93%	139.8°C



Fig. 3: Percentage of anticoagulant effect in terms of concentration using PT reagent.

Anticoagulant activity

Our synthesized products were estimated for the anticoagulant activity, employing PT and APTT tests which have been reacted with our samples and human plasma citrated; also, that the clotting time which was calculated by a timer show the appropriate percentage of coagulation. Since the comparison was made with the PT and APTT reagents, the results gotten which are presented in the Fig 3 and Fig 4 indicate that the N-aryl thiourea derivatives have a high anticoagulant activity.

Structure-activity relationship

By performing the anticoagulant activity, and comparing with the results obtained with the PT and APTT reagents, there were different positives results that depend on the different structures of compounds synthesized. (Fig 5, Fig 6). While for unsymmetrical thiourea derivatives the presence of the three Methyl groups (Product 8) slightly affects the anticoagulant activity. For symmetrical thiourea derivatives there is difference in the electronegative effect of the substituent that exist at the "meta" position, it has a great influence on the anticoagulant activity; which means that the product 9 has a better activity compared to the rest in this range. Lastly, the product 4 exhibits the excellent anticoagulant activity in comparison with all the preceding products due to the presence of the chlorine molecule at the "meta" position, which has increased the electronegative effect leading to a development of the anticoagulant activity. Finally, regarding the anticoagulant activity, the thiourea derivatives showed a good activity, due to the electronegative substituent



Fig. 4: Percentage of anticoagulant effect in terms of concentration using APTT reagent.



Fig. 5: Curve represents Percentage changes of anticoagulant effect in terms of concentration using PT reagent.

DFT Calculations

DFT calculations were performed for compound 1 and 6, as representative molecules, in order to get insights into the molecular geometry and chemical reactivity of the investigated compounds. First, a full geometry optimization of all possible tautomers and conformers of compounds 1 and 6 has been carried out at B3LYP/6-311G (d,p) level in the gas phase and the obtained results are shown in Fig 7 and 8. It was found that both compounds present six different molecular geometries with relative energies ranging from -4.38 to 17.36 kcal/mol for compound 1 and -4.39 to 11.94 kcal/mol for compound 6. In both cases, the thiocarbonyl form was found to be significantly stablethan the enolic forms. For example, the thiocarbonyl form of compound 1 is stable by 14.41 kcal/mol than its enolic form. These results suggest that the thiocarbonyl form is the dominant tautomer for both compound 1 and compound 6. The position of NH bonds has also been found to have a considerable effect on the stability of molecules. For the two compounds, the most stable geometry is obtained when the NH bonds are in the Anti-configuration.



Fig. 6: Curve represents Percentage changes of anticoagulant effect in terms of concentration using APTT reagent.



Fig 7. The most stable conformers of compound 1 and their relative energy in kcal/mol



Fig. 8: The most stable conformers of compound 6 and their relative energy in kcal/mol [66].

After having determined the most stable geometry of molecules 1 and 6, we then investigated their chemical reactivity by computing their frontier molecular orbitals (FMOs). FMO represents the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO). These orbitals are important parameters that can be used to predict the chemical reactivity of the studied compounds [60-62]. The HOMO is the highest molecular orbital occupied by at leastone electron. The distribution of this orbital determines the sites for nucleophilic attacks and its energy is correlated with the electron-donating ability. LUMO is the lowest energy orbital unoccupied by an electron and determines the sites of electrophilic attacks. The computed FMOs energies and distributions of compounds 1 and 6are reported in Fig 9. As shown, the FMOs of both compounds present similar distributions. The HOMOs are mainly localized on the sulfur atom with very small contributions on the nitrogen atoms. Whereas the LUMOs are distributed over the entire molecule. This suggests that the sulfur atom is the most reactive site as a nucleophile, while the entire molecule can undergo electrophilic attack. The FMOs of both compounds have also comparable energies. The energies of HOMOs are -5.72 and -5.82 eV and those of LUMOs are -1.04 and -1.35 eV for compounds 1 and 6, respectively. Compared to recognized antioxidants, the HOMO energies of compounds 1 and 6 are comparable to those of BHT (-5.74 eV) and Trolox (-5.39 eV), but higher than that of ascorbic acid (-6.50 eV) [63]. This suggests that 1 and 6 may be good radical scavengers. The difference between HOMO and LUMO energy of compounds 1 and 6 is 4.68 and 4.47 eV, respectively. This small energy gap reflects the high chemical reactivity of the studied compounds.



Fig. 9: HOMO and LUMO distributions and energies of compounds 1 and 6.

Conclusion

In summary, this study is based on our previous works. We have synthesized nine thiourea derived from phenyl-isothiocyanate. The nine compounds were obtained by the reaction of phenyl-isothiocyanate with various primary amines, which gave good yields. Their structures were confirmed by spectral analysis (UV, IR and NMR 1H, 13C). The anticoagulant activity has been realized using PT and APTT reagents, the results showed that the tested compounds exhibit a good anticoagulant activity. The synthetic benefits of the presented method are reflected in the operational simplicity, mild reaction conditions, short reaction time, high purity and the excellent yield of products.

Acknowledgments

The authors wish to thank the bioactive molecules and chiral separation laboratory of Tahri Mohammed University, Bechar, Algeria, for their support in order to have good results. They also thank the dialysis laboratory, Hajout, Tipaza, Algeria for their help to realize the biologic activity.

References

1. M. Nencki, Zur kenntniss des sulfoharnstoffs, *Ber. Dtsch. Chem. Ges*., **6**, 598 (1873).
2. A.L. Lourenço, M.S. Saito, L.E.G. Dorneles, G.M. Viana, P.C. Sathler, L.C.S. Aguiar, Synthesis and Antiplatelet Activity of Antithrombotic Thiourea Compounds: Biological and Structure-Activity Relationship Studies, *Molecules*., **20**,7147(2015).
3. C. Lucia, de Sequeira Aguiar, M. Gil, V. Viana, Marcus, dos Santos Romualdo, V. Marcio, S. Costa, S. Bruno, A. Bonato, Simple and Green Procedure for the Synthesis of N-Benzylthioureas, *Lett. Org. Chem*., **8**, 540 (2011);
4. N. Azizi, A.Yadollahy, A.G. Ourimi, Ultrasound-assisted rapid sustainable synthesis of substituted thiourea, *Monatsh Chem*., **145**, 1675 (2014).
5. C.G.M. Oliveira, V.W. Faria, G.F. Andrade, E. D'Elia, M.F. Cabral, B.A. Cotrim, Synthesis of thiourea derivatives and its evaluation as corrosion inhibitor for carbon steel, *Phosphorus, Sulfur, and Silicon*., **190**, 1366 (2015).
6. Z. Ngaini, W. S.H.W. Zulkiplee, A. N. Abd Halim. One-Pot multicomponent synthesis of thiourea derivatives in cyclotriphosphazenes moieties, *Hindawi J. Chem*., **509129**, 7 (2017).
7. N. Morakot, W. Rakrai, S. Keawwangchai, C. Kaewtong, B. Wanno. Design and synthesis of thiourea based receptor containing naphthalene as oxalate selective sensor, *J. Mol. Model*., **16**, 129(2010).
8. G. Sanna, S. Madeddu, G. Giliberti, S. Piras, M. Struga, M. Wrzosek, et al. Synthesis and biological evaluation of novel indole-derived thioureas, *Molecules*., **23**, 2554(2018).
9. I.V. Kulakov, O.A. Nurkenov, B.T. Ibragimov, S.A. Talipov, Z.M. Zhambekov, A.A. Ainabaev, et al. Synthesis of thiourea derivatives of the alkaloid anabasine and crystal structure of N-(Anabasino-1-thiocarbinyl) furan-2-carboxamide, *Chem. Nat. Compd*., **45**, 209(2009).
10. C. Yinan, J. Wenbo, X. Guiying, M. Yichao, Z. Yanqin, L. Honglian. Synthesis of thiophene formyl thiourea derivatives and fungicidal activity, *Chinese J. Org. Chem*., **36**, 2683 (2016).
11. A. Kowalczyk, A.M. Pieczonka, M. Rachwalski, Stanisław Lesniak, P. Staczek. Synthesis and evaluation of biological activities of aziridine derivatives of urea and thiourea, *Molecules*., **23**, 145(2018).
12. J. Wu, Q. Shi, Z. Chen, M. He, L. Jin, D. Hu. Synthesis and bioactivity of pyrazole acyl thiourea derivatives, *Molecules*., **17**,5139 (2012).
13. J. Stefańska, K.Stępień, A. Bielenica, M. Wrzosek, M. Struga. Antistaphylococcal activity of selected thiourea derivatives, *Pol. J. Microbiol*., **65**, 451 (2016).
14. A. Z. Halimehjani, F. Farahbakhsh. Synthesis of thioureas in ionic liquid medium, *J. Sulphur Chem*., **34**, 284(2013).
15. N. Azizi, E. Farhadi. Rapid and highly efficient synthesis of thioureas in biocompatible basic choline hydroxide. *J. Sulphur Chem*., **38**, 548 (2017).
16. J.D. Bloom, M.J. DiGrandi, R.G. Dushin, K.J. Curran, A.A. Ross, E.B. Norton, et al.Thiourea inhibitors of herpes viruses. part 1: bis-(aryl)thiourea inhibitors of CMV, *Bioorg. Med. Chem. Lett*., **13**, 2929 (2003).
17. M.B. Krajačić, P. Novak, M. Dumić, M. Cindrić, H.Č. Paljetak, N. Kujundžić. Novel ureas and thioureas of 15-membered Azalides with antibacterial activity against key respiratory pathogens, *Eur. J. Med. Chem*., **44**, 3459 (2009).
18. S. K. Sharma, Y. Wu, N. Steinbergs, ML. Crowley, A.S. Hanson, R.A. Casero, et al. (Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators, *J. Med. Chem*., **53**, 5197(2010).
19. I.V. Dael, H.M. Lehmenn, M. Froryen, J.Balzarini, S.V. Calenbergh. Rational Design of

5'-Thiourea-substituted α-thymidine analogues as thymidine monophosphate kinase inhibitors capable of inhibiting mycobacterial growth, *S. J. Med. Chem*., **50**, 5281 (2007).

20. C. D. Bădiceanu, D.C. Nuță, A.V. Missir, M. Hrubaru, C. Delcaru, L.M.Dițu, et al. Synthesis, structural, physico-chemical characterization and antimicrobial activity screening of new thiourea derivatives, *Farmacia*., **66**, 149 (2018).
21. M. Glory, M. Kiranmai, GV. Karunakar, S.C. Narendra. Synthesis, antimicrobial activity and docking studies of novel urea and thiourea derivatives, *J. Pharm. Biol. Sci*., **11**, 10 (2016).
22. J. N. Asegbeloyin, E. E. Oyeka, I. Babahan, O. Okpareke. Novel synthesis of metal complexes of palmitoyl thioureas and their antimicrobial activities, *J. Chem Soc. Nigeria*., **43**, 550(2018).
23. M.M. Ghorab, M.S.Alsaid, M.S. A El-Gaby, M. M. Elaasser, Y. M. Nissan. Antimicrobial and anticancer activity of some novel fluorinated thiourea derivatives carrying sulfonamide moieties: synthesis, biological evaluation and molecular docking, *Chem. Cent. J*., **11**, 32 (2017).
24. S. Kumar, W. Purcell, J. Conradie, R. R. Bragg, E. H. G. Langner. Synthesis, characterization, computational and antimicrobial activities of a novel iridium thiourea complex, *New. J. Chem*., **41**, 10919 (2017).
25. C. Obiol-Pardo, G. Alcarraz-Vizán, M. Cascante, J. Rubio-Martinez. Diphenyl urea derivatives as inhibitors of transketolase: A structure-based virtual screening, *plos one*., **7**,e322276 (2012).
26. C. Sun, X. Zhang, H. Huang, P. Zhou. Synthesis and evaluation of a new series of substituted acyl(thio)urea and thiadiazolo [2,3-a] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase, *Bioorg. Med. Chem*., **14**, 8574 (2006).
27. J. Sun, S. Cai, H. Mei, J. Li, N. Yan, Q. Wang, et al. Molecular docking and QSAR studies on substituted Acyl(thio)urea and thiadiazolo [2,3-α] pyrimidine derivatives as potent inhibitors of influenza virus neuraminidase, *Chem. Biol. Drug. Des*., **76**, 245 (2010).
28. Z. Zhong, R. Xing, S. Liu, L. Wang, S. Cai, P. Li. Synthesis of acyl thiourea derivatives of chitosan and their antimicrobial activities in vitro, *Carbohydr. Res*., **343**, 566 (2008).
29. S. Y. Ke, S.J. Xue. Synthesis and herbicidal activity of N-(o-fluoro phenoxy acetyl) thioureas derivatives and related fused heterocyclic compounds, *Arkivoc*., **10**, 63 (2006).
30. W. Fenhua, Q. Zhanglan, H. Qin. Synthesis and fungicidal activity of 1,3,4- Oxadiazole substituted acylthioureas, *Front. Chem.China*., **1**, 112 (2006).
31. Ruswantoa, A.M. Miftaha, D.H. Tjahjonoa, Siswandonoc. Synthesis and in vitro cytotoxicity of 1-Benzoyl-3-methyl thiourea Derivatives, *Procedia Chem*., **17**, 157 (2015).
32. J-H. Hu, L-C. Wang , H. Liu, T-B. Wei . Biological activities studies and phase transfer catalysts promoting the one-pot synthesis of N-Aryl-N′-(4-Ethyloxy Benzoyl)-thiourea derivatives, *Phosphorus Sulfur Silicon Relat. Elem*., **181**, 2691 (2006).
33. K. Sanphanya, S. K.Wattanapitayakul, O. Prangsaengtong, M. Jo, K.Koizumi,N. Shibahara, et al. Synthesis and evaluation of 1-(substituted)-3-prop-2-ynylureas as antiangiogenic agents, *Bioorg. Med. Chem. lett*., **22**, 3001 (2012).
34. M. Shoaib, Shafiullah, M. Ayaz, M. Nawaz Tahir, S. W. Ali Shah. Synthesis, characterization, crystal structures, analgesic and antioxidant activities of thiourea derivatives, *J. Chem. Soc. Pak*., **38**,479 (2016).
35. A. Ranise, A.Spallarossa,O.Bruno, S.Schenone, P.Fossa, G.Menozzi et al. Synthesis of N-substituted-N-acylthioureas of 4-substituted piperazines endowed with local anaesthetic, antihyperlipidemic, antiproliferative activities and antiarrythmic, analgesic, antiaggregating actions, *II Farmaco*., **58**,765 (2003).
36. J. Liu, P. Liao, J. Hu, H. Zhu, Y. Wang, Y. Liet al. Synthesis and antitumor activities of chiral dipeptide thioureas containing an alpha-aminophosphonate moiety, *Molecules*., **22**, 238 (2017).
37. H. Peng, Y. Liang, L. Chen, L. Fu, H. Wang, H. He. Efficient synthesis and biological evaluation of 1, 3-benzenedicarbonyl dithioureas, *Bioorg. Med. Chem. Lett*., **21**, 1102 (2011).
38. A. Ranise, F. Bondavalli, O. Bruno, S. Schenone, D. Donnoli, C. Parrillo et al. 1-Acyl-,3-acyl- and 1,3-diacyl-3-furfuryl-1-phenylthioureas with platelet antiaggregating and other activities, *Farmaco*., **46**, 1203 (1991).
39. S. Claridge, F. Raeppel, M-C. Granger, N. Bernstein, O. Saavedra, L. Zhan et al. Discovery of a novel and potent series of thieno[3,2-b] pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases. Bioorg, *Med. Chem. Letters*., **18**, 2793, (2008).
40. S. N. Manjula, N. M. Noolvi, K. V. Parihar, S. A. M. Reddy, V. Ramani, A. K. Gadad et al. Synthesis and antitumor activity of optically active thiourea and their 2-aminobenzothiazole derivatives: A novel class of anticancer agents, *European J. Med. Chem*., **44**, 2923 (2009).

41. R. Vig, C. Mao, T. K. Venkatachalam, L. Tuel-Ahlgren, E. A. Sudbeck, F. M. Uckun. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reverse transcriptase, *Bioorg. Med.Chem*., **6**,1789 (1998).
42. F. Eshkil, H. Eshghi, A. S. Saljooghi, M. Bakavoli, M. Rahimizadeh. Benzothiazole thiourea derivatives as anticancer agents: Design, synthesis, and biological screening, *Russian J. Bioorg. Chem*., **43**, 576 (2017).
43. S. Adhikari, O. Hussain, R.M. Phillips , W. Kaminsky, M. R. Kollipara. Neutral and cationic half-sandwich arene d6metal complexes containing pyridyl and pyrimidyl thiourea ligands with interesting bonding modes: Synthesis, structural and anti-cancer studies, *Appl. Organomet. Chem*., **32**, 4476(2018).
44. P.A. Wang, J.T. Feng, X.Z. Wang, M.Q. Li. A new class of glucosyl thioureas: Synthesis and larvicidal activities, *Molecules*., **21**, 925(2016).
45. G. M. Viana, D. C. Soares, M.V. Santana, L. H. Amaral, P. W. Meireles, R. P. Nunes, et al. Antileishmanial thioureas: Synthesis, biological activity and in silico evaluations of new promising derivatives, *Chem. Pharm. Bull*., **65**, 911(2017).
46. L. S. Seddiki, N. Belboukhari, A. ould el hadj khelil, M. R. Sulaiman, M. Yakoubi, K. Sekkoum, et al. Investigation of the analgesic and anti-inflammatory activities of Launaea Nudicaulis from southwest of Algeria, Biomed. *J. Sci. Tech. Res*., **23**, 17173 (2019).
47. K. Fyad, N. Belboukhari, A. OuldEl Hadj Khelil, K. Sekkoum. Analgesic and anti-inflammatory activity of aqueous extract of Bubonium graveolens, *Biomed. Res. Ther*., **7**, 4002 (2020).
48. H. Benlakhdar, N. Belboukhari, K. Sekkoum, A. Cheriti, Ha. B. Keskinkaya, S. Akkal, Chemical Composition and Anti-inflammatory Activity of the Essential Oil of Echium humile (Boraginaceae) in vivo from South-West of Algeria, *Jordan J. Biol. Sci*., **14**,17 (2021).
49. M. Yakoubi, N. Belboukhari, K. Sekkoum, M. Bouchekara, H. Y. Aboul-Enein. Evaluation of analgesic and anti-inflammatory activities of Warionia saharae essential oil, *As. Pac. J. Mol. Biol. Biotechnol*., **29**,10 (2021).
50. M. Ameur, K. Sekkoum, F. Gonazles, J. Comez-Carpintero, C. Menendez, N. Belboukhari, Enantioseparation and antioxidant activity of novel diarylpyrazoline derivatives, *Chirality*., **34**, 1389(2022).
51. F. Z. Mimouni, N. Belboukhari, K. Sekkoum, H. Y. Aboul-Enein. Novel Gatifloxacin3-Carboxamide derivatives as anti-tumor agents: synthesis, enantioseparation, and molecular docking, *Curr. Anal. Chem*., **18**, 1108 (2022).
52. M. Taha, N. H. Ismail, W. Jamil, K. M. Khan, U.Salar, S.M. Kashif, et al. Synthesis and evaluation of unsymmetrical heterocyclic thioureas as potent b-glucuronidase inhibitors, *Med Chem Res*., **24**, 3166(2015).
53. M.J. Frisch, G.W. Trucks, H.B. Schlegel, Scuseria GE, Robb MA, Cheeseman JR, Scalmani G, Barone V, Mennucci B, Petersson GA, Nakatsuji H, Caricato M, Li X, Hratchian HP, Izmaylov AF, Bloino J, Zheng G, Sonnenberg JL, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, Montgomery JA, Peralta JE, Ogliaro F, Bearpark M, Heyd JJ, Brothers E, Kudin KN, Staroverov VN, Kobayashi R, Normand J, Raghavachari K, Rendell A, Burant JC, Iyengar SS, Tomasi J, Cossi M, Rega N, Millam JM, Klene M, Knox JE, Cross JB, Bakken V, Adamo C, aramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Martin RL, Morokuma K, Zakrzewski VG, Voth GA, Salvador P, Dannenberg JJ, Dapprich S, Daniels AD, Farkas Ö, Foresman JB, Ortiz JV, Cioslowski J, Fox DJ Gaussian 09, Revision E.01. Wallingford, CT (2009).
54. A.D. Becke, Density-functional exchange-energy approximation with correct asymptotic, *behavior. Phys. Rev*., A **38**, 3098(1988).
55. P.C. Hariharan, J.A. Pople, The influence of polarization functions on molecular orbital hydrogenation energies, *Theor. Chim. Acta*., **28** ,213(1973).
56. J. Tirado-Rives, W.L. Jorgensen, Performance of B3LYP Density Functional Methods for a Large Set of Organic Molecules, *J. Chem. Theor. Comput*., **4**, 297(2008).
57. I.Y. Zhang, J. Wu, X. Xu, Extending the reliability and applicability of B3LYP. *Chem. Com*., **46**, 3057 (2010).
58. H. Boulebd, Y.D. Lahneche I.A. Khodja, M. Benslimane, A. Belfaitah, New Schiff bases derived from benzimidazole as efficient mercury-complexing agents in aqueous medium, *J. Mol. Stru*., **1196**,58(2019).
59. H. Boulebd, DFT study of the antiradical properties of some aromatic compounds derived from antioxidant essential oils: C–H bond vs. O–H bond, *Free Radical Research*, **53**, 1125 (2019).
60. I. Amine Khodja, H. Boulebd, Synthesis, biological evaluation, theoretical investigations, docking study and ADME parameters of some

1,4-bisphenylhydrazone derivatives as potent antioxidant agents and acetylcholinesterase inhibitors, *Mol. Divers*., **25**, 279 (2021).

61. H. Boulebd, Comparative study of the radical scavenging behavior of ascorbic acid, BHT, BHA and Trolox: Experimental and theoretical study, *J. Mol. Struct*. **1201**: 127210 (2020).
62. A. Laoufi, N. Belboukhari, K. Sekkoum, H.Y. Aboul-Enein, Synthesis and chiral separation of atropisomers of 4,5-Di methyl Δ4 N-phenyl N-aryl imidazoline-2- thione derivatives, *Chirality*. **33**, 264 (2021).
63. N. Belboukhari, N. Cheriti, A. Djafri, A. Roussel Synthesis and characterization of some derivatives of 4,5-Di-Methyl Δ^4 N-aryl N-Ethyle imidazoline-2- thione, Asian *J. Chem*., **20**, 2491(2008).
64. N.N, Mohd Nabil L, Sin Ang Conformational and topology analysis of diphenyl thiourea and Di-aryl halyd thiourea compounds using DFT, *Indones. J.Chem*., **20**, 264 (2020).